ZA200607349B - Flat system for using in the oral cavity - Google Patents
Flat system for using in the oral cavity Download PDFInfo
- Publication number
- ZA200607349B ZA200607349B ZA200607349A ZA200607349A ZA200607349B ZA 200607349 B ZA200607349 B ZA 200607349B ZA 200607349 A ZA200607349 A ZA 200607349A ZA 200607349 A ZA200607349 A ZA 200607349A ZA 200607349 B ZA200607349 B ZA 200607349B
- Authority
- ZA
- South Africa
- Prior art keywords
- sheet
- intermediate layer
- layer
- water
- sealing
- Prior art date
Links
- 210000000214 mouth Anatomy 0.000 title claims description 17
- 238000007789 sealing Methods 0.000 claims description 37
- 229920003169 water-soluble polymer Polymers 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 26
- 229920000642 polymer Polymers 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims description 9
- 238000002844 melting Methods 0.000 claims description 9
- 230000008018 melting Effects 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 6
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 6
- YPFDHNVEDLHUCE-UHFFFAOYSA-N propane-1,3-diol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000000243 solution Substances 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 4
- 239000000155 melt Substances 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 239000003925 fat Substances 0.000 claims description 3
- 229940051250 hexylene glycol Drugs 0.000 claims description 3
- 239000006215 rectal suppository Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 229960003604 testosterone Drugs 0.000 claims description 3
- ISHXLNHNDMZNMC-VTKCIJPMSA-N (3e,8r,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-3-hydroxyimino-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-ol Chemical compound O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C\1 ISHXLNHNDMZNMC-VTKCIJPMSA-N 0.000 claims description 2
- YSGQGNQWBLYHPE-CFUSNLFHSA-N (7r,8r,9s,10r,13s,14s,17s)-17-hydroxy-7,13-dimethyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C1C[C@]2(C)[C@@H](O)CC[C@H]2[C@@H]2[C@H](C)CC3=CC(=O)CC[C@@H]3[C@H]21 YSGQGNQWBLYHPE-CFUSNLFHSA-N 0.000 claims description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 2
- RSEPBGGWRJCQGY-RBRWEJTLSA-N Estradiol valerate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2 RSEPBGGWRJCQGY-RBRWEJTLSA-N 0.000 claims description 2
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 claims description 2
- RPLCPCMSCLEKRS-BPIQYHPVSA-N desogestrel Chemical compound C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPLCPCMSCLEKRS-BPIQYHPVSA-N 0.000 claims description 2
- 229960004976 desogestrel Drugs 0.000 claims description 2
- AZFLJNIPTRTECV-FUMNGEBKSA-N dienogest Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@](CC3)(O)CC#N)CC3)C3=C21 AZFLJNIPTRTECV-FUMNGEBKSA-N 0.000 claims description 2
- 229960003309 dienogest Drugs 0.000 claims description 2
- 229930182833 estradiol Natural products 0.000 claims description 2
- 229960002568 ethinylestradiol Drugs 0.000 claims description 2
- GCKFUYQCUCGESZ-BPIQYHPVSA-N etonogestrel Chemical compound O=C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 GCKFUYQCUCGESZ-BPIQYHPVSA-N 0.000 claims description 2
- SIGSPDASOTUPFS-XUDSTZEESA-N gestodene Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](C=C4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 SIGSPDASOTUPFS-XUDSTZEESA-N 0.000 claims description 2
- 229960002667 norelgestromin Drugs 0.000 claims description 2
- 229960003484 testosterone enanthate Drugs 0.000 claims description 2
- 239000008186 active pharmaceutical agent Substances 0.000 claims 3
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims 1
- 238000007792 addition Methods 0.000 claims 1
- METQSPRSQINEEU-UHFFFAOYSA-N dihydrospirorenone Natural products CC12CCC(C3(CCC(=O)C=C3C3CC33)C)C3C1C1CC1C21CCC(=O)O1 METQSPRSQINEEU-UHFFFAOYSA-N 0.000 claims 1
- 229960004845 drospirenone Drugs 0.000 claims 1
- METQSPRSQINEEU-HXCATZOESA-N drospirenone Chemical compound C([C@]12[C@H]3C[C@H]3[C@H]3[C@H]4[C@@H]([C@]5(CCC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 METQSPRSQINEEU-HXCATZOESA-N 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 229960005352 gestodene Drugs 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 230000011218 segmentation Effects 0.000 claims 1
- 230000003637 steroidlike Effects 0.000 claims 1
- 150000005846 sugar alcohols Polymers 0.000 claims 1
- VOCBWIIFXDYGNZ-IXKNJLPQSA-N testosterone enanthate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCCCC)[C@@]1(C)CC2 VOCBWIIFXDYGNZ-IXKNJLPQSA-N 0.000 claims 1
- 239000010410 layer Substances 0.000 description 117
- 239000004480 active ingredient Substances 0.000 description 27
- 239000000047 product Substances 0.000 description 21
- -1 drospirenon Chemical compound 0.000 description 12
- 244000246386 Mentha pulegium Species 0.000 description 11
- 235000016257 Mentha pulegium Nutrition 0.000 description 11
- 235000004357 Mentha x piperita Nutrition 0.000 description 11
- 235000001050 hortel pimenta Nutrition 0.000 description 11
- 239000000758 substrate Substances 0.000 description 10
- 239000000463 material Substances 0.000 description 9
- 239000012530 fluid Substances 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 229940116364 hard fat Drugs 0.000 description 5
- 239000013067 intermediate product Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 239000008177 pharmaceutical agent Substances 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 239000003270 steroid hormone Substances 0.000 description 3
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 2
- VZWGRQBCURJOMT-UHFFFAOYSA-N Dodecyl acetate Chemical compound CCCCCCCCCCCCOC(C)=O VZWGRQBCURJOMT-UHFFFAOYSA-N 0.000 description 2
- 239000004129 EU approved improving agent Substances 0.000 description 2
- 229920003080 Povidone K 25 Polymers 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- 229920001002 functional polymer Polymers 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000010327 methods by industry Methods 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 229960002715 nicotine Drugs 0.000 description 2
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 2
- 229940082615 organic nitrates used in cardiac disease Drugs 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 229920006254 polymer film Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- BHIZVZJETFVJMJ-UHFFFAOYSA-N 2-hydroxypropyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(C)O BHIZVZJETFVJMJ-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- CSAVDNHVPJNKTC-UHFFFAOYSA-N 5-methyl-2-propan-2-ylcyclohexan-1-ol;5-methyl-2-propan-2-ylphenol;2,2,4-trimethyl-3-oxabicyclo[2.2.2]octane Chemical compound CC(C)C1CCC(C)CC1O.CC(C)C1=CC=C(C)C=C1O.C1CC2CCC1(C)OC2(C)C CSAVDNHVPJNKTC-UHFFFAOYSA-N 0.000 description 1
- QZCLKYGREBVARF-UHFFFAOYSA-N Acetyl tributyl citrate Chemical compound CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC QZCLKYGREBVARF-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229920003149 Eudragit® E 100 Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- 230000006750 UV protection Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- FLZQKRKHLSUHOR-UHFFFAOYSA-N alosetron Chemical compound CC1=NC=N[C]1CN1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FLZQKRKHLSUHOR-UHFFFAOYSA-N 0.000 description 1
- 229960003550 alosetron Drugs 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 229920006217 cellulose acetate butyrate Polymers 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000001877 deodorizing effect Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- QQQMUBLXDAFBRH-UHFFFAOYSA-N dodecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCOC(=O)C(C)O QQQMUBLXDAFBRH-UHFFFAOYSA-N 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000004049 embossing Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229960004766 estradiol valerate Drugs 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000011256 inorganic filler Substances 0.000 description 1
- 229910003475 inorganic filler Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 229960004400 levonorgestrel Drugs 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 229940076522 listerine Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000010309 melting process Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229960005343 ondansetron Drugs 0.000 description 1
- 239000012766 organic filler Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 238000009516 primary packaging Methods 0.000 description 1
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 1
- 229940026235 propylene glycol monolaurate Drugs 0.000 description 1
- 239000011814 protection agent Substances 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- NTHPAPBPFQJABD-LLVKDONJSA-N ramosetron Chemical compound C12=CC=CC=C2N(C)C=C1C(=O)[C@H]1CC(NC=N2)=C2CC1 NTHPAPBPFQJABD-LLVKDONJSA-N 0.000 description 1
- 229950001588 ramosetron Drugs 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- RNVYQYLELCKWAN-UHFFFAOYSA-N solketal Chemical compound CC1(C)OCC(CO)O1 RNVYQYLELCKWAN-UHFFFAOYSA-N 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- UDSFVOAUHKGBEK-CNQKSJKFSA-N testosterone undecanoate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCCCCCCCC)[C@@]1(C)CC2 UDSFVOAUHKGBEK-CNQKSJKFSA-N 0.000 description 1
- 229960000746 testosterone undecanoate Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Description
Flat System For Using in the Oral Cavity (Specification)
The invention relates to a flat system for use in the oral cavity and a method for manufacturing it. This system is comprised of at least one upper and at least one lower water-soluble covering layer. Between the upper and lower covering layers, at least one intermediate layer is provided, which has a smaller area than the covering layers and is recessed along the edge of the flat system.
Prior Art
Flat preparations for use in the oral cavity are known. Typically, these are water-soluble polymer films that break down rapidly in the mouth by dissolving in the saliva. The polymer film can contain ingredients intended for oral or dental care or for deodorizing, disinfecting, or freshening purposes, which essentially act in the oral cavity or in the nasal/throat cavity.
Products from this field include, for example, Eclipse Flash from the
Wrigley Company or Listerine PocketPaks from the Pfizer Company.
In addition to cosmetic uses, pharmaceutical agents can also be contained in the flat preparations — such products are currently in development.
As examples of the prior ar, reference is hereby made to the patents DE 2432925, DE 19956486A1, DE 19652257A1, DE 19652188, DE 101076589, and
WO 03/011259 A1.
It is advantageous to be able to administer pharmaceutical products without drinking water, to eliminate the swallowing that some find unpleasant, and to offer numerous possibilities for the active ingredient to perform its function in the oral cavity or in the bloodstream via the oral cavity, for example through transmucosal absorption.
The disadvantages of flat drug formats according to the prior art are as follows: — water-soluble polymer films are manufactured from an aqueous solution, at temperatures typically above 100°C and with relatively long drying times since the removal of water necessitated by its high thermal capacity in comparison
@ 2 Co PE to organic solvents is a process that consumes a lot of energy. These process conditions can be unsuitable for easily volatile or thermally unstable active ingredients, _ or the active ingredients can easily decompose chemically at high temperatures in aqueous solution. — The flat drug formats typically contain the active ingredient distributed evenly over the surface. If shapes other than rectangular or square are used, then some of the active ingredient is wasted in the cutting process. — Loading with the active ingredient, as it increases in concentration, impairs the film-forming property of water-soluble polymers (e.g. increasing brittleness) and the loading capacity of the films is reduced by this effect. — The water-soluble films are manufactured using highly hydrophilic polymers that naturally have a low solubility for lipophilic active ingredients frequently encountered in pharmaceutical applications, e.g. steroid hormones. As a result, the films have a low loading capacity for lipophilic active ingredients, which can then only be loaded in the form of a crystal suspension or as multiphase systems, €.g. an emulsion. _ The water-soluble polymer films are as a rule comprised of highly functional polymers that have a large number of hydroxyl or carboxyl functions in the polymer chain. These highly functional polymers are in a position to undergo numerous chemical interactions with pharmaceutical agents, which can easily lead to stability problems. — In order to be processable, water-soluble polymer films typically require a residual moisture content that assures sufficient flexibility or prevents brittleness. The residual water content, however, has a negative effect on the chemical stability of active ingredients in medicines.
The object of the present invention, therefore, is to overcome these disadvantages of conventional flat pharmaceutical products for use in the oral cavity.
; Sh
According to the present invention, this object is attained by means of a flat system for use in the oral cavity, comprised of at least one upper and at least one lower water-soluble covering layer; at least one intermediate layer is provided between the upper and lower covering layers. This intermediate layer has a smaller area than the covering layers because the intermediate layer is recessed along the edge of the flat system.
According to the present invention, the upper and lower covering layer can be attached to each other in a sealed fashion along the edge of the flat system.
The width of the sealed seam can be 0.3 — 3 mm, preferably 0.5 — 2 mm, and particularly preferably 0.75 to 1.5 mm.
In the flat system according to the present invention, the overall thickness of this flat system at its thickest point can be 50 to 500 pm, preferably 100 to 300 pm, and particularly preferably 150 to 250 um.
According to the present invention, the intermediate layer can be water- soluble and have a melting point between 30 and 120°C, preferably between 50 and 100°C, and particularly preferably between 60 and 90°C.
The intermediate layer can also be water-insoluble.
Advantageous embodiments of the flat system according to the present invention are comprised of the solid preparation of the intermediate layer, which melts at temperatures between 30 and 45°C, preferably between 32 and 40°C, and particularly preferably between 35 and 38°C.
The intermediate layer can be comprised of a matrix that is used in the manufacture of rectal suppositories, preferably made of one or more hard fats (Adeps solidus) as described in the monograph of the European Pharmacopeia.
The intermediate layer can also be an oleaginous solution, suspension, or emulsion.
According to the present invention, the intermediate layer can be segmented within the flat product by virtue of the fact that the upper and lower \ covering layer are attached to each other in a sealed fashion in this region.
The intermediate layer can also contain at least one pharmaceutical agent in a dissolved or undissolved form.
@
Furthermore, the solubility of the pharmaceutical agent in the intermediate layer can be at least n times 10, preferably n times 10-100, where n represents the solubility of the covering layers.
A method for manufacturing a flat system is claimed in which, in a first method step, an intermediate layer composed of a lipophilic pharmaceutical preparation is deposited in a thin layer onto a water-soluble polymer layer and then covered with a second water-soluble polymer layer, whereupon in a subsequent method step, the upper and lower polymer layers are attached to each other in segments by means of heat sealing; mechanical pressure at the sealing points displaces the intermediate layer situated between the upper and lower polymer layer and the sealed covering layers form fully enclosed compartments in the intermediate layer.
In the method according to the present invention, the residual moisture in the water-soluble polymer films can be set to a value that improves the sealing capacity, preferably a value of 1 — 10% and particularly preferably 2 — 5% (m/m) water content.
In addition, in the method according to the present invention, the residual moisture in the water-soluble polymer films can be reduced by means of a drying process after the manufacture of the flat capsules.
In the method according to the present invention, the sealing capacity of the water-soluble polymer films can also be assured by means of softening additives from the group of hydrophilic fluids, preferably from the group of polyvalent alcohols with 3 to 6 carbon atoms (Cs — Cg), particularly preferably glycerol, 1,2-propylene glycol, 1,3-propylene glycol, 1,3-butane diol, hexylene glycol, or dipropylene glycol.
The flat system according to the present invention can contain one or two steroid hormones for hormone replacement therapy or for hormonal contraception.
The steroid hormones can be levonorgestrel, gestoden, dienogest, desogestrel, 3-keto-desogestrel, norelgestromin, drospirenon, estradiol, ethinyl estradiol, estradiol valerate, testosterone, testosterone undecanoate,
@ testosterone enanthate, 7-alpha-methyl-19-nortestosterone, or its fluorine- containing derivatives.
In the flat system according to the present invention, an active ingredient can be selected from the group of organic nitrates (used to treat angina 5 pectoris), in particular glycerol trinitrate, or an active ingredient from the group of antiemetics, in particular the 5-HT; receptor antagonists and particularly preferably from the group of ondansetron, granistron, ramosetron, alosetron, or the pharmaceutically acceptable salts thereof.
The flat system can also contain a nicotine base or a pharmaceutically acceptable salt thereof.
With both organic nitrates and nicotine, it is necessary to deliver the active ingredient into the bloodstream as quickly as possible directly via the oral mucous membranes.
It is also possible for the flat system according to the present invention to contain active ingredients for the treatment of geriatric illnesses, in particular morbus Alzheimer, morbus Parkinson, dementia-inducing diseases as well as active ingredients for treatment of severe psychiatric illnesses such as schizophrenia or psychoses. These therapy fields are partly distinguished by a reduced capacity or willingness to swallow, thus making it advantageous to administer drugs via the oral cavity.
Surprisingly, the stated object can be attained by selecting a flat product with a multilayered construction in which the function of the water-soluble polymer film and the function of the active ingredient substrate are provided separately in different layers; the active ingredient-containing layer is embodied in the form of an intermediate layer with an area smaller than the total area of the system due to the fact that the intermediate layer is recessed along the edge of the flat system.
In addition, the water-soluble polymer films surprisingly have the capacity to be processed in a heat-sealable fashion. This surprisingly turns out to be the case, even when a lipophilic, oleaginous, or wax-like intermediate layer is contained between these layers before the heat sealing.
@
By means of the present invention, it is possible to embed an intermediate layer in an envelope of hydrophilic, water-soluble polymer films, in a form similar to that of an extremely flattened capsule.
The intermediate layer can be comprised of a fluid, semisolid, or wax-like solid preparation. When used in the oral cavity, first, the envelope of water- soluble polymer films dissolves. Then, the intermediate layer breaks down by melting, by dissolving in the saliva, or by the two processes occurring simultaneously.
In the case in which the intermediate layer melts, an embodiment is preferred in which the compound melts at typical oral cavity temperatures of between 32 and 37°C.
In this way, the intermediate layer is practically imperceptible to the user and the mouthfeel is significantly more pleasant than that of an intermediate layer that remains solid. This also facilitates and accelerates the melting- induced release of the active ingredient from the lipophilic layer. With the use of wax-like intermediate layers, melting should not yet occur at temperatures below 30°C in order to prevent the melting from occurring while the drug is being stored.
Suitable materials for the manufacture of the external water-soluble covering layers include water-soluble polymers from the group of polyvinyl alcohols with a hydrolysis grade of 75-99% (e.g. Mowiol® types), polyvinyl pyrrolidone, hydrophilic cellulose derivatives such as hydroxypropyl cellulose, hydroxymethyipropy! cellulose, or carboxymethyl! cellulose, pullulan or maltose, hydrophilic starch derivatives such as carboxymethyl starch, alginates or gelatines, and other polymers known from the prior art.
The formulation and process engineering treatment of the intermediate layer are essentially determined by three requirements: 1. The intermediate layer must quickly dissolve in the mouth by melting or dissolving in the saliva or a combination of the two. 2. In the preferred case, the intermediate layer is applied in a coat directly onto a water-soluble polymer layer and, from a process-engineering standpoint,
® 7 should require no solvents that can dissolve the polymer layer functioning as the coating substrate. 3. The intermediate layer must be thermoplastically deformable in order to be able to recede during production of the heat seal between the covering layers.
A wax-like, low-melting formulation is a preferable possibility for the formulation of the lipophilic intermediate layer. An example of this is the manufacture of rectal suppositories or vaginal suppositories. A selection of low- melting matrixes with melting points that can be selected from within a wide range can be made from the group of Softisan® and Witepsol® hard fats.
Suitable substrate substances are also described in the monograph “Hard Fat” (Adeps solidus) of the European Pharmacopeia.
Alternatively, oleaginous, viscous solutions can be used as the intermediate layer. Suitable substrate substances include pharmaceutically common oils and lipophilic fluids that are preferably largely flavor-neutral, e.g. saturated triglycerides (e.g. Miglyol 812), isopropyl myristate, or isopropyl palmitate. Thickening agents can be added to these oleaginous solutions to increase the viscosity. With no claim as to completeness, these preferably include polymers from the group of polyacrylates (e.g. Eudragit® E 100 or
Plastoid ® B), polyvinyl pyrrolidone (Kollidon® 25, 30, 90, or VA 64), polyvinyl acetate (e.g. Kollidon® SR), polyethylene glycol, or lipophilic cellulose derivatives (e.g. cellulose ethyl ether or cellulose acetate butyrate).
With no claim as to completeness, suitable polymer components of the intermediate layer include, for example, polyvinyl pyrrolidone (PVP) or its copolymers, e.g. Kollidon® 25, 30, 90, or VA 64, and polyethylene glycols (macrogols), with molecule masses of greater than 2000 Da.
It is also possible to add to the formulation of the intermediate layer, with no claim as to completeness, additives from the groups of softeners, tensides, solutizers, penetration improving agents, parting compounds, antioxidants, light and UV-protection agents, pigments, colorants, flavor correctants, organic or inorganic fillers and fragrances.
@
In this connection, the solutizers and penetration-improving agents are of particular importance:
On the one hand, the flat capsules according to the present invention have only a small interior volume, which reduces their loading capacity for active ingredients. Furthermore, it can be advantageous if the active ingredients contained are already completely or predominantly absorbed via the mucous membranes in the mouth instead of being absorbed only after being swallowed into the gastrointestinal tract.
The formulation of the intermediate layer should have the highest possible dissolving power for the active ingredient provided and solutizers can be used to this end. The solutizers must be selected so that they do not threaten the integrity of the water-soluble covering layers as a result of solubilizing, dissolving, or powerful softening.
Suitable solutizers include, for example, fatty acid esters of saturated fatty acids with chain lengths of 6 to 18 carbon atoms with monovalent to trivalent aliphatic alcohols having 2 to 4 carbon atoms (e.g. ethyl oleate, propylene glycol monolaurate, glycerol monooleate), fatty alcohol ethers of fatty alcohols having 6 to 18 carbon atoms with polyethylene glycol (e.g. BRIJ® products), fatty acid esters of fatty acids having 6 to 18 carbon atoms with polyethylene glycol (e.g.
MYRJ® products), esters of fatty alcohols having 6 to 18 carbon atoms with carboxylic acids having 2 to 3 carbon atoms (lauryl lactate or lauryl acetate), sorbitan fatty acid esters (e.g. SPAN® products), sorbitan polyethylene glycol ethers of fatty acid esters (e.g. TWEEN® products), citric acid esters (e.g. triethyl citrate or acetyl tributyl citrate), diethylene glycol monothethylether (Transcutol®), propylene carbonate, solketal, glycofurol, tracetin, and cyclodextrine.
The compounds of the intermediate layer and the covering layers are advantageously selected so that in the intermediate layer, the solubility of the active ingredient in the intermediate layer is significantly greater than in the covering layers. This reduces potential undesirable chemical decomposition reactions of the active ingredient after migration into the covering layers.
@
To manufacture the flat systems according to the present invention, first, a water-soluble polymer film is manufactured by applying a solution in a coat onto a web-like substrate material and subsequently drying it. Alternatively, the film can also be manufactured by means of a solvent-free hot melting process.
The weight per unit area of the polymer layer is 25 — 200 g/m?, preferably 40 to 150 g/m?, and particularly preferably 60 to 100 g/m’.
An intermediate layer is applied onto this starting material (polymer film on a substrate material, e.g. nonstick coated paper), from the side of the water- soluble polymer. This intermediate layer is preferably comprised of a medium- viscosity lipophilic fluid or the molten mass of a lipophilic compound. The lipophilic fluid or compound can be applied, for example, with the aid of a sheet die, a coating knife, a roller application unit, or a knife caster.
The weight per unit area of this intermediate layer is 25 — 300 g/m?, preferably 30 to 200 g/m?, and particularly preferably 40 to 150 g/m?
The intermediate layer is preferably not deposited all the way up to the edge of the underlying polymer layer; instead, a margin of at least 05to5cmis left at the edge in order to prevent the intermediate layer from coming out at the edge in the subsequent process steps.
The exposed surface of the intermediate layer, once it has resolidified after cooling, is covered with a second water-soluble polymer layer that as a rule, is of the same composition and produced with the same manufacturing method as the lowermost, first polymer layer. Preferably, however, the second water- soluble polymer layer is first removed from its substrate material and then laminated as a single layer onto the intermediate layer.
In a second process step, the composite made up of the substrate material, first water-soluble polymer layer, lipophilic intermediate layer, and second water-soluble polymer layer is subjected, with a suitable sealing mask, to a heat sealing coming from the uppermost, freely exposed polymer layer and consequently from the side furthest from the web-shaped substrate material.
The intermediate layer between the water-soluble polymer films is first melted as needed and then displaced by mechanical pressure at the parts to be
@ sealed until the two water-soluble polymer films are joined to each other at these points with a permanent bond by means of heat sealing.
For heat-sealing capacity purposes, it can be advantageous to maintain a residual moisture in the water-soluble polymer films or to first adjust it by moistening.
The sealing capacity of the water-soluble polymer films can also be increased by means of softening additives from the group of hydrophilic fluids, preferably by means of additives from the group of multivalent alcohols with 3 to 6 carbon atoms (C3-Cs), particularly preferably glycerol, 1,2-propylene glycol, 1,3-propylene glycol, 1,3-butane diol, hexylene glycol, or dipropylene glycol.
In cases in which a residual moisture is required for the sealing capacity, it can be necessary to dry the product after manufacture and to set the residual moisture to a lower value than required during sealing in order, for example, to increase the long-term chemical stability of the product.
In order to manufacture individually dosed formats, the upper and lower polymer layers are sealed together along a provided contour line so thata quantity of the lipophilic intermediate layer defined by the area is completely enclosed in individual dose fashion.
The individual doses of the active ingredient-containing intermediate layer are formed in this process step, which means that the sealing mask used must have corresponding dimensional accuracy of plus or minus 5% or better in order to be able to maintain the pharmaceutically required dosing accuracy.
With regard to the design of the sealing masks, it is advantageous to round the edges of the sealing contour in order not to exert unnecessarily high shear forces on the typically rather brittle water-soluble polymer films.
Finally, the manufactured flat products are mechanically cut or punched out along the sealing seams and thus divided up into individual forms or groups of individual forms.
The remaining widths of the sealed edge regions of the flat products should be kept as narrow as possible since in these regions, the water-soluble polymer films of the upper and lower covering layer jointly compose a particularly
@ thick zone that can be expected to have the slowest dissolving speed in the mouth and therefore to have a negative effect on the mouthfeel. The width of the sealed seam should be 0.3 to 3 mm, preferably 0.5 to 2 mm, and particularly preferably 0.75 to 1.5 mm.
Fig. A1 shows a schematic, cross-sectional view of a flat system:
An upper covering layer (1) and a lower covering layer (2) cooperate to enclose an internal intermediate layer (3). In the case of Fig. A1, the two outer layers have a flat cavity, whereas in Fig. A2, the cavity for accommodating the intermediate layer is provided only in one of the two covering layers. The covering layers (1) and (2) can be identical or have differing structures.
Fig. A3 shows a flat system equipped with two separate chambers (3 and 4) formed with the aid of an additional covering layer (5).
Fig. B shows a flat intermediate product after the heat-sealing step; both longitudinally and transversely, the flat product can have a number of separate, active ingredient-containing segments of the intermediate layer that are transformed into the end products in additional process steps by being cut or punched out. Figs. C1 through C5 show top views of various embodiment forms of the flat product according to the present invention. They are essentially intended to illustrate the possible embodiment forms. While the products C2 and
C3 are more visually acceptable to consumers, the products C1, C4, and C5 have a higher coefficient of utilization of the flat intermediate product and produce less waste; this waste, however, does not contain any active ingredient.
By contrast with Fig. C4, Fig. C5 illustrates the possibility that the contour line of the inner, active ingredient-containing intermediate layer does not have to follow the outer contour line of the flat product.
Fig. D shows an example of a flat product with a number of active ingredient-containing segments (3). This product represents a multi-dose product that can be divided up into individual doses.
Figs. E1 through E4 illustrate a heat-sealing process step according to the present invention. A stamping, heat-sealing tool (7) presses the laminate —
@ which is comprised of an upper covering layer (1), a lower covering layer (2), and an internal intermediate layer (3) on a web of substrate material (6) — against a counterpressure surface (8) of the sealing station; either the sealing tool alone or both the sealing tool and the counterpressure plate are heated.
This process step can also be executed using a counterpressure plate equipped with a flat cavity, which produces an approximately symmetrical cross- sectional form of the flat system according to the present invention. Fig. E3 schematically depicts the result of such a sealing procedure.
In Fig. E4, rounded regions are provided at the locations on the sealing mask (7) indicated with arrows, which regions lead to a reduction of the mechanical deformation stress on the covering layer (1) and therefore to a reduction in the risk of tears or leaks in the sealing seam. This technique can naturally also be applied to the two-sided form according to Fig. E3.
Figs. E1 through E4 illustrate the relevant process step on a flatbed sealing die for a discontinuous operation in which the laminate web is brought to a halt during the process step. Naturally, this process step can also be executed on rotary systems equipped with correspondingly contoured sealing and embossing rollers and a continuously traveling laminate web.
For the primary packaging of the systems according to the present invention, reference is hereby made to the patents DE 19800682, DE 10008165,
DE 10144287, DE 10102818, DE 10159746A1, and DE 10143120A1 and to the prior art cited therein.
Exemplary Embodiments
Example 1: Three-layer flat capsule with a wax-like semisolid intermediate layer
Intermediate layer: semisolid
Materials: Eclipse™ peppermint strips (3x2cm) (Wrigley)
Softisan 100 (hard fat) (Sasol) temperature-controlled water bath beaker single-use Pasteur pipettes
® 13 sealing pliers
Implementation: a lipophilic intermediate layer
Softisan 100 is heated in the water bath until a clear molten mass forms.
With the aid of a Pasteur pipette, the Softisan 100 is applied uniformly to the entire Eclipse™ peppermint strip (3x2cm). After the hard fat begins to solidify, another Eclipse™ peppermint strip (3x2cm) is placed precisely onto the lipophilic layer. The three-layer intermediate product is then sealed for approx. 5 sec. on all four sides with the aid of sealing pliers heated to approx. 160°C.
Example 2: Five-layer flat capsule with 2 semisolid intermediate layers
Softisan 100 is heated in the water bath until a clear molten mass forms.
With the aid of a Pasteur pipette, Softisan 100 is applied uniformly to the entire
Eclipse™ peppermint strip (3x2cm). After the hard fat begins to solidify, another
Eclipse™ peppermint strip (3x2cm) is placed precisely onto the lipophilic layer.
A second hard fat layer is applied, which, after it solidifies, is in turn covered precisely with an Eclipse™ peppermint strip (3x2cm). The five-layer intermediate product is then sealed for approx. 8 sec. on all four sides with the aid of sealing pliers heated to approx. 160°C.
Example 3: Three-layer flat capsule with an oleaginous intermediate layer
Materials: Eclipse™ peppermint strips (3x2cm) (Wrigley Co.) viscous paraffin single-use Pasteur pipettes sealing pliers
Execution:
With the aid of a Pasteur pipette, viscous paraffin is applied uniformly to the entire Eclipse™ peppermint strip (3x2cm). Another Eclipse™ peppermint strip (3x2cm) is placed precisely onto the lipophilic layer. The three-layer intermediate product is then sealed for approx. 5 sec. on all four sides with the aid of sealing pliers heated to approx. 160°C.
Definitions and calculations used in examples 1 — 3:
In order to determine the weight per unit area (FG), the manufactured multilayered products are individually weighed and the respective areas are determined. The weight cf 10 Eclipse™ peppermint strips is determined and the average is calculated. The dimensions are correspondingly determined and the area is calculated.
The conversion of the units is taken into account in the calculation formula.
Strips: FG, ==4¥10
FG,: weight per unit area (g/m°) my. mass (average) (mg)
A: area (cm?) m
FlatCaps: FG, =—*10
FG: weight per unit area (g/m?) my: mass (average) (mg) lipophilic intermediate layer: FG = FG - FGp
In the examples, values of between 45 and 55 g/m? were determined for the weight per unit area of the Eclipse™ peppermint strips.
The weight per unit area of the Softisan layer in example 1 was 132 g/m.
The weight per unit area of the oleaginous layer in example 3 was 80 g/m’
Claims (18)
1. Sheet-like pharmaceutical system for use in the oral cavity, consisting of at least an upper and at least a lower water-soluble covering layer, with at least one intermediate layer being provided between the upper and the lower covering layer, characterized in that the intermediate layer has a smaller surface area than the covering layers since the intermediate layer is recessed along the edge of the sheet-like system.
2. Sheet-1like system according to Claim 1, characterized in that between the upper covering layer and the intermediate layers and between the lower covering layer and the intermediate layer at least one steroidal hormone, preferably levonorgetrel, gestodene, dienogest, desogestrel, 3- keto-desogestrel, norelgestromin, drospirenone, oestradiol, ethinyloestradiol, oestradiol valerate, testosterone, testosterone undecancate, testosterone oenanthate, 7alpha-methyl-19-nortestosterone or its fluorine-containing derivatives, is present as active pharmaceutical ingredients.
3. Sheet-1like system according to Claim 1 or 2, characterized in that the upper and the lower covering layer are connected together in the edge region of the sheet-like system by sealing.
4. Sheet-like system according to Claim 3, characterized in that the width of the sealing seam is 0.3-3 mm, preferably 0.5-2 mm. AMENDED SHEET
PCT/EP2005/001076
® 6.
5. Sheet-like system according to one or more of the preceding claims, characterized in that the total thickness of the sheet-like system at its thickest point is 50 to 500 um, preferably 100 to 300 pm.
6. Sheet-like system according to one or more of the preceding claims, characterized in that the intermediate layer is water-soluble and has a melting point between 30 and 120°C, preferably between 50 and 100°C.
7. Sheet-like system according to one or more of Claims 1 to 5, characterized in that the intermediate layer is designed to be water-insoluble.
8. Sheet-1like system according to Claim 7, characterized in that the intermediate layer is a solid preparation which melts at temperatures between 30 and 45° Celsius, preferably between 32 and 40°C.
9. Sheet-like system according to Claim 8, characterized in that the intermediate layer consists of a basic composition which is used to produce rectal suppositories, preferably of one or more hard fats (Adeps Solidus) complying with the monograph of the European Pharmacopoeia.
10. Sheet-1like system according to Claim 7, characterized in that the intermediate layer is an oily solution, suspension or emulsion. AMENDED SHEET
. PCT/EP2005/001076 ® -17-
11. Sheet-like system according to one or more of the preceding claims, characterized in that the intermediate layer has a segmentation within the sheet-like structure, since the upper and lower S covering layer are connected together in this region by sealing.
12. Sheet-like system according to one or more of the preceding claims, characterized in that the intermediate layer contains at least one active pharmaceutical ingredient in dissolved or undissolved form.
13. Sheet-like system according to Claim 12, characterized in that the solubility of the active pharmaceutical ingredient in the intermediate layer is at least n times 10, preferably n times 10-100, where n is the solubility of the covering layers.
14. Process for producing a sheet-like system according to one or more of the preceding claims, characterized in that - an intermediate layer of a lipophilic pharmaceutical preparation 1s applied in thin layer to a water-soluble polymer layer, - is then covered with a second water-soluble polymer layer, - the upper and the lower polymer layer are connected together segmentally by heat sealing, with the intermediate layer being displaced under the influence of mechanical pressure at the sealing points between upper and lower polymer layer, and with compartments which are completely enclcsed by AMENDED SHEET
. PCT/EP2005/001076 ® -18- the sealed covering layers being additionally formed in the intermediate layer.
15. Process according to Claim 14, characterized in that the residual moisture content in the water-soluble polymer films is adjusted to a value which improves the sealability, preferably 1-10% (m/m) water content.
16. Process according to Claim 15, characterized in that the residual moisture content in the water-soluble polymer films after production of the flat capsules is reduced by a drying process.
17. Process according to one or more of Claims 14 to 16, characterized in that the sealability of the water- soluble polymer films 1s ensured by plasticizing additions from the group of hydrophiic liquids, preferably from the group of polyhydric alcohols with 3 to 6 carbon atoms (C3-C¢), particularly preferably glycerol, 1,2-propylene glycol, 1, 3- propylene glycol, 1,3-butanediol, hexylene glycol or dipropylene glycol.
18. Sheet-1like system according to Claim 1, substantially as herein described with reference to and as illustrated in any of the examples and accompanying drawings.
18. Process according to Claim 14, substantially as herein described with reference to and as illustrated in any of the examples and accompanying drawings. AMENDED SHEET
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US54139604P | 2004-02-03 | 2004-02-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200607349B true ZA200607349B (en) | 2008-01-30 |
Family
ID=40635426
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200607349A ZA200607349B (en) | 2004-02-03 | 2006-09-01 | Flat system for using in the oral cavity |
Country Status (1)
Country | Link |
---|---|
ZA (1) | ZA200607349B (en) |
-
2006
- 2006-09-01 ZA ZA200607349A patent/ZA200607349B/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070298084A1 (en) | Flat System for Using in the Oral Cavity | |
JP4063331B2 (en) | Instantly wettable water-soluble thin film or water-soluble layer applied to the mouth | |
WO2019079402A2 (en) | Improved delivery systems for moieties including cbd enhanced combinations, formulations and chimeras | |
JP3021661B2 (en) | Transdermal release devices for drug-containing adhesive composites | |
BRPI0709148A2 (en) | stabilized compositions containing labile alkaline drugs | |
CA2329556A1 (en) | Method of preparing a watersoluble film | |
TW200808382A (en) | Film-shaped drug forms for use in the oral cavity (wafers) | |
BRPI0907298B1 (en) | SOLUBLE PREPARATION IN WATER, SOLID AND FILM FORMAT COMPOSING POLYVINYL ALCOHOL AND OILY SUBSTANCE, AND METHOD FOR PRODUCING THEM | |
EP3784184A1 (en) | New medical devices, delivery vehicles and manufacturing thereof | |
CN113382725A (en) | Oral film | |
JP2010158173A (en) | Edible film, edible film composition, and method for producing edible film laminated body | |
JP5722539B2 (en) | Poultice | |
CN101843603A (en) | Transdermal delivery of hormones without the need of penetration enhancers | |
CN1913878B (en) | Transdermal delivery of hormones without the need of penetration enhancers | |
JP5209274B2 (en) | Swallowing assist film, swallowing assist hollow film joined body, and continuous production method thereof | |
ZA200607349B (en) | Flat system for using in the oral cavity | |
US20090169606A1 (en) | Low Flexural Strength Transdermal Tobacco Alkaloid Patch | |
US20090246264A1 (en) | Transdermal Tobacco Alkaloid Patch | |
JP5497358B2 (en) | Edible laminated film and method for producing the same | |
MXPA06008827A (en) | Flat system for using in the oral cavity | |
CN101229144B (en) | Percutaneous absorption patch containing gestodene and/or estrogen | |
JPH0335285B2 (en) | ||
EA009977B1 (en) | Flat system for using in the oral cavity | |
CA2892105A1 (en) | Topical drug for treating aphthae | |
DE19736315A1 (en) | Active agent containing device, for dermal use |